Business Description
Neumora Therapeutics Inc
NAICS : 541714
SIC : 2833
ISIN : US6409791000
Total Employee Number:
92Description
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.76 | |||||
Equity-to-Asset | 0.46 | |||||
Debt-to-Equity | 0.76 | |||||
Debt-to-EBITDA | -0.24 | |||||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -17.1 | |||||
3-Year EPS without NRI Growth Rate | -19 | |||||
3-Year FCF Growth Rate | -18.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 18.19 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 26.77 | |||||
9-Day RSI | 37.91 | |||||
14-Day RSI | 42.27 | |||||
3-1 Month Momentum % | -35.11 | |||||
6-1 Month Momentum % | -29.13 | |||||
12-1 Month Momentum % | -36.24 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.09 | |||||
Quick Ratio | 5.09 | |||||
Cash Ratio | 4.88 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -4.7 | |||||
Shareholder Yield % | -16.5 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -154.88 | |||||
ROA % | -110.83 | |||||
ROIC % | -2496.3 | |||||
3-Year ROIIC % | 267.19 | |||||
ROC (Joel Greenblatt) % | -28074.34 | |||||
ROCE % | -126.55 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 3.85 | |||||
Price-to-Tangible-Book | 3.83 | |||||
EV-to-EBIT | -0.84 | |||||
EV-to-EBITDA | -0.84 | |||||
EV-to-Forward-Revenue | 89.53 | |||||
EV-to-FCF | -0.95 | |||||
| Price-to-Net-Current-Asset-Value | 3.83 | |||||
| Price-to-Net-Cash | 4.27 | |||||
Earnings Yield (Greenblatt) % | -119.05 | |||||
FCF Yield % | -69.82 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:NMRA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Neumora Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.33 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 205.78 | ||
| 14-Day RSI | 42.27 | ||
| 14-Day ATR ($) | 0.129824 | ||
| 20-Day SMA ($) | 1.6275 | ||
| 12-1 Month Momentum % | -36.24 | ||
| 52-Week Range ($) | 0.83015 - 3.65 | ||
| Shares Outstanding (Mil) | 185.28 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Neumora Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Neumora Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 103 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-06 16:30 | In 12 days | ||
| Second quarter earnings results for 2026 | 2026-08-06 | In 11 days | ||
| General meeting for 2026 | 2026-05-27 16:00 | 1.84 (-3.66%) | ||
| Guidance call for 2026 | 2026-05-19 13:35 | 1.77 (-3.80%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 2.33 (+0.43%) | ||
| 25th Annual Needham Virtual Healthcare Conference | 2026-04-13 10:15 | 2.04 (-2.39%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-30 08:00 | 2.33 (-6.43%) | ||
| Annual report for 2025 | 2026-03-30 | 2.33 (-6.43%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-30 | 2.33 (-6.43%) |
Show
Entries
Neumora Therapeutics Inc Frequently Asked Questions
What is Neumora Therapeutics Inc(NMRA)'s stock price today?
The current price of NMRA is $1.50. The 52 week high of NMRA is $3.65 and 52 week low is $0.83.
When is next earnings date of Neumora Therapeutics Inc(NMRA)?
The next earnings date of Neumora Therapeutics Inc(NMRA) is 2026-08-06 Est..
Does Neumora Therapeutics Inc(NMRA) pay dividends? If so, how much?
Neumora Therapeutics Inc(NMRA) does not pay dividend.
Guru Commentaries on NAS:NMRA
No articles.
Press Release
Articles on Neumora Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers